Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 118

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 118
---
 activities with respect to the Depositary Shares for the applicable restricted period, as defined in Regulation M, prior to the
commencement of the distribution. In addition, the selling shareholders will be subject to applicable provisions of the Exchange Act and
the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Depositary Shares
by the selling shareholders or any other person. We will make copies of this prospectus available to the selling shareholders and have
informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance
with Rule 172 under the Securities Act).

| 65 |

<div align='center'>EXPENSES OF THE OFFERING</div>

The following table sets
forth the expenses payable by us in connection with the sale and distribution of the securities being registered hereby. All amounts shown,
other than the SEC registration fee, are estimates:

| SEC registration fee    | $ |    904 |
| Printing and engraving  |   |  5,000 |
| Accounting services     |   | 15,000 |
| Legal fees and expenses |   | 50,000 |
| Miscellaneous           |   |  5,000 |
| Total                   | $ | 75,904 |

<div align='center'>LEGAL MATTERS</div>

Certain legal matters in connection
with the validity of the securities offered hereby will passed upon for us by Brown Rudnick LLP, London, United Kingdom.

<div align='center'>EXPERTS</div>

The financial statements as
of December 31, 2024, and for the year then ended, incorporated by reference into this prospectus and in the registration statement have
been so incorporated in reliance on a report PKF Littlejohn LLP, an independent registered accounting firm, given on authority of said
firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2024 contains an explanatory
paragraph regarding our ability to continue as a going concern.

PKF Littlejohn LLP, London,
United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

The financial statements of
Biodexa Pharmaceuticals PLC as of December 31, 2023, and for each of the three years in the period then ended, incorporated by reference
into this prospectus and in the registration statement, have been so incorporated in reliance on a report of For